{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:42:44Z","timestamp":1792590164431,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shaanxi Provincial Key Research and Development Plan","award":["2025SF-YBXM-310"],"award-info":[{"award-number":["2025SF-YBXM-310"]}]},{"name":"the Doctor Training and Promotion Project of Xijing Hospital","award":["XJZT25CX44"],"award-info":[{"award-number":["XJZT25CX44"]}]},{"name":"the Doctor Training and Promotion Project of Xijing Hospital","award":["XJZT24LY39"],"award-info":[{"award-number":["XJZT24LY39"]}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2025-JC-QYCX-080"],"award-info":[{"award-number":["2025-JC-QYCX-080"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Heart failure with reduced ejection fraction (HFrEF) patients remain at substantial risk despite quadruple guideline-directed medical therapy (GDMT [ARNI\u2009+\u2009SGLT2 inhibitor\u2009+\u2009\u03b2-blocker\u2009+\u2009MRA]). Data on vericiguat in stable HFrEF patients without recent worsening heart failure receiving contemporary quadruple GDMT are limited. This observational study aimed to explore the efficacy and safety of vericiguat in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 450 adult patients with LVEF\u2009&lt;\u200945% were enrolled (200 received quadruple GDMT plus vericiguat, 250 received quadruple GDMT alone). After 1:1 propensity score matching (PSM), 144 well-matched pairs were identified. The primary outcome was the composite of cardiovascular death or first HF hospitalization within 12 months. Secondary outcomes included changes in NYHA functional class, KCCQ-12 scores, and occurrence of hypotension. Due to the non-randomized design, all efficacy findings except the primary composite endpoint are considered exploratory. Trial Registration: ChiCTR, ChiCTR2500095278. Registered 4 January 2025. Retrospectively registered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over 12 months, the primary composite endpoint occurred in 5.56% of the vericiguat group versus 9.03% of the control group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.365; HR 0.616, 95% CI 0.255\u20131.486). No statistically significant differences were observed for cardiovascular death or all-cause mortality. Exploratory analyses showed that the vericiguat group had higher KCCQ-12 Overall Summary Scores (91.61\u2009\u00b1\u20099.56 vs. 87.93\u2009\u00b1\u200911.25,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003) and a greater proportion achieving a\u2009\u2265\u20095-point improvement (94.44% vs. 81.25%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001). NYHA functional class distribution also differed between groups (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.029). Hypotension rates were similar between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among HFrEF patients without recent worsening, vericiguat did not significantly reduce the primary composite endpoint at 12 months. Exploratory observations suggest potential associations with improved quality of life and functional class without increased hypotension risk. These hypothesis\u2011generating findings require confirmation in adequately powered randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-06319-1","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:34:04Z","timestamp":1784604844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vericiguat for heart failure with reduced ejection fraction on quadruple therapy without recent worsening heart failure: an exploratory real-world cohort study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9793-2984","authenticated-orcid":false,"given":"Peng","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boda","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genrui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"20","key":"6319_CR1","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol. 2017;70(20):2476\u201386.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"6319_CR2","doi-asserted-by":"publisher","first-page":"e008406","DOI":"10.1161\/CIRCHEARTFAILURE.121.008406","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Chai K, Du M, Wang S, Cai JP, Li Y, et al. Prevalence and Incidence of Heart Failure Among Urban Patients in China: A National Population-Based Analysis. Circ Heart Fail. 2021;14(10):e008406.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"6319_CR3","first-page":"531","volume":"37","author":"M Mcdonald","year":"2021","unstructured":"Mcdonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, et al. CCS\/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Can J Cardiol. 2021;37(4):531\u201346.","journal-title":"Can J Cardiol"},{"issue":"25","key":"6319_CR4","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1093\/eurheartj\/ehaa183","volume":"41","author":"KF Docherty","year":"2020","unstructured":"Docherty KF, Jhund PS, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J. 2020;41(25):2379\u201392.","journal-title":"Eur Heart J"},{"issue":"14","key":"6319_CR5","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1080\/14656566.2021.1937121","volume":"22","author":"JS Hulot","year":"2021","unstructured":"Hulot JS, Trochu JN, Donal E, Galinier M, Logeart D, De Groote P, et al. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. Expert Opin Pharmacother. 2021;22(14):1847\u201355.","journal-title":"Expert Opin Pharmacother"},{"issue":"20","key":"6319_CR6","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883\u201393.","journal-title":"N Engl J Med"},{"issue":"9","key":"6319_CR7","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/ejhf.1787","volume":"22","author":"F Kramer","year":"2020","unstructured":"Kramer F, Voss S, Roessig L, Igl BW, Butler J, Lam CSP, et al. Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2020;22(9):1675\u201383.","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"6319_CR8","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u20131032.","journal-title":"Circulation"},{"issue":"6","key":"6319_CR9","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"TM Maddox","year":"2021","unstructured":"Maddox TM, Januzzi JL Jr., Allen LA, Breathett K, Butler J, Davis LL, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772\u2013810.","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"6319_CR10","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA Mcdonagh","year":"2021","unstructured":"Mcdonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"key":"6319_CR11","doi-asserted-by":"crossref","unstructured":"Saldarriaga CI, Zannad F, Mcmullan CJ, Xing A, Gates D, Anstrom KJ et al. Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial. Eur J Heart Fail, 2025;27(8):1426\u20131435.","DOI":"10.1002\/ejhf.3598"},{"issue":"2","key":"6319_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ejhf.3501","volume":"27","author":"YNV Reddy","year":"2025","unstructured":"Reddy YNV, Butler J, Anstrom KJ, Blaustein RO, Bonaca MP, Corda S, et al. Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial. Eur J Heart Fail. 2025;27(2):209\u201318.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"6319_CR13","first-page":"2003","volume":"92","author":"KA Chacko","year":"1995","unstructured":"Chacko KA, AHA Medical\/Scientific S. 1994 revisions to classification of functional capacity and objective assessment of patients with diseases of the heart. Circulation. 1995;92(7):2003\u20135.","journal-title":"Circulation"},{"issue":"5","key":"6319_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1161\/CIRCOUTCOMES.115.001958","volume":"8","author":"JA Spertus","year":"2015","unstructured":"Spertus JA, Jones PG. Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire. Circ Cardiovasc Qual Outcomes. 2015;8(5):469\u201376.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"36","key":"6319_CR15","doi-asserted-by":"publisher","first-page":"9442","DOI":"10.1002\/anie.201302588","volume":"52","author":"M Follmann","year":"2013","unstructured":"Follmann M, Griebenow N, Hahn MG, Hartung I, Mais FJ, Mittendorf J, et al. The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed Engl. 2013;52(36):9442\u201362.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"7","key":"6319_CR16","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1515\/hsz-2018-0155","volume":"399","author":"P Sandner","year":"2018","unstructured":"Sandner P. From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators. Biol Chem. 2018;399(7):679\u201390.","journal-title":"Biol Chem"},{"issue":"12","key":"6319_CR17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.21037\/atm-22-2583","volume":"10","author":"Y Cai","year":"2022","unstructured":"Cai Y, Zhang B, Shalamu A, Gao T, Ge J. Soluble guanylate cyclase (sGC) stimulator vericiguat alleviates myocardial ischemia-reperfusion injury by improving microcirculation. Ann Transl Med. 2022;10(12):662.","journal-title":"Ann Transl Med"},{"issue":"6a","key":"6319_CR18","doi-asserted-by":"publisher","first-page":"g11","DOI":"10.1016\/j.amjcard.2005.07.016","volume":"96","author":"M Gheorghiade","year":"2005","unstructured":"Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96(6a):g11\u20137.","journal-title":"Am J Cardiol"},{"issue":"4","key":"6319_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","volume":"81","author":"SJ Greene","year":"2023","unstructured":"Greene SJ, Bauersachs J, Brugts JJ, Ezekowitz JA, Lam CSP, Lund LH, et al. Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week. J Am Coll Cardiol. 2023;81(4):413\u201324.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"6319_CR20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/ejhf.1810","volume":"22","author":"J Butler","year":"2020","unstructured":"Butler J, Khan MS, Mori C, Filippatos GS, Ponikowski P, Comin-Colet J, et al. Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2020;22(6):999\u20131005.","journal-title":"Eur J Heart Fail"},{"issue":"10510","key":"6319_CR21","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(25)01665-4","volume":"406","author":"J Butler","year":"2025","unstructured":"Butler J, Mcmullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, et al. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2025;406(10510):1341\u201350.","journal-title":"Lancet"},{"issue":"6","key":"6319_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/eurheartj\/ehaf655","volume":"47","author":"J Butler","year":"2026","unstructured":"Butler J, Fioretti F, Mcmullan CJ, Anstrom KJ, Barash I, Bonaca MP, et al. Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial. Eur Heart J. 2026;47(6):683\u201397.","journal-title":"Eur Heart J"},{"issue":"10510","key":"6319_CR23","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(25)01682-4","volume":"406","author":"F Zannad","year":"2025","unstructured":"Zannad F, O\u2019connor C M, Butler J, Mcmullan CJ, Anstrom KJ, Barash I, et al. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet. 2025;406(10510):1351\u201362.","journal-title":"Lancet"},{"issue":"6","key":"6319_CR24","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/ejhf.2874","volume":"25","author":"M Metra","year":"2023","unstructured":"Metra M, Tomasoni D, Adamo M, Bayes-Genis A, Filippatos G, Abdelhamid M, et al. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2023;25(6):776\u201391.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"6319_CR25","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/ejhf.838","volume":"19","author":"S Zaman","year":"2017","unstructured":"Zaman S, Zaman SS, Scholtes T, Shun-Shin MJ, Plymen CM, Francis DP, et al. The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets. Eur J Heart Fail. 2017;19(11):1401\u20139.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"6319_CR26","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/ejhf.1450","volume":"21","author":"C O\u2019connor","year":"2019","unstructured":"O\u2019connor C, Fiuzat M, Mulder H, Coles A, Ahmad T, Ezekowitz JA, et al. Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score. Eur J Heart Fail. 2019;21(6):770\u20138.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"6319_CR27","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamacardio.2020.6455","volume":"6","author":"CSP Lam","year":"2021","unstructured":"Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, et al. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. JAMA Cardiol. 2021;6(6):706\u201312.","journal-title":"JAMA Cardiol"},{"issue":"21","key":"6319_CR28","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"M Gheorghiade","year":"2015","unstructured":"Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, et al. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. JAMA. 2015;314(21):2251\u201362.","journal-title":"JAMA"},{"issue":"11","key":"6319_CR29","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","volume":"8","author":"JA Ezekowitz","year":"2020","unstructured":"Ezekowitz JA, O\u2019connor C M, Troughton RW, Alemayehu WG, Westerhout CM, Voors AA, et al. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. JACC Heart Fail. 2020;8(11):931\u20139.","journal-title":"JACC Heart Fail"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06319-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06319-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06319-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:04:07Z","timestamp":1792587847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06319-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6319"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06319-1","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Air Force Medical University (Approval No.: KY20242169-F-1). This study has been retrospectively registered in the Chinese Clinical Trial Registry (ChiCTR) under registration number ChiCTR2500095278. Written informed consent was obtained from all participants prior to enrollment. The study adhered to the Declaration of Helsinki and followed the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines for cohort studies.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript contains no individual person\u2019s data in any form.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"948"}}